DNER and Duchenne muscular dystrophy: BET inhibitors ability to concurrently counteract different processes, such as oxidative stress and inflammatory pathways (Fig. 8), may be a key advantage to pharmacologically target different aspects of the DMD pathology, through an epigenetic approach.